Preapproval Inspections: Industry Urges FDA Transition To “For Cause”

FDA should consider moving to "for cause" preapproval inspections as part of its quality systems initiative, drug manufacturers told FDA at the Product Quality Research Institute/FDA conference in Washington, D.C. April 24